Business Wire

Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations

17.9.2025 16:35:00 CEST | Business Wire | Press Release

Share

Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/

Bacardi announces new roles for Dave Ingram and Nicole Zukowski.

Dave Ingram has been appointed to the role of Chief People & Business Transformation Officer, responsible for delivering the next chapter for building an organization that is fit for the future. In this role, Dave will continue to prioritize talent management, succession planning, performance management, and capability building which are core to setting a legacy of more than 163 years for the success of generations to come. Dave, a member of the Bacardi Global Leadership Team, most recently served as Chief Supply Chain Officer, where he led the end-to-end supply chain for the company’s portfolio of brands — from leading its operations sites and logistics across the globe, to ensuring the consistent exceptional quality and taste of Bacardi products and overseeing the sourcing of all raw materials. Dave brings a true global view to the role and a passion for connecting people and cultures stemming from his experiences living in Singapore, Amsterdam, Shanghai, Mexico, the United Kingdom, and Bermuda. Dave, who joined Bacardi in 2022, continues to report to Chief Executive Officer Mahesh Madhavan and will be based at the company’s global headquarters in Bermuda, pending approval by the Bermuda Immigration Authority.

This news follows the previously announced retirement of Scott Northcutt after more than 16 years leading the people organization at Bacardi and serving on the Global Leadership Team. Scott will serve as Senior Vice President of Family Development Programs.

With Dave’s move, Bacardi promotes Nicole Zukowski to Chief Supply Chain Officer. She joins the Global Leadership Team reporting to Mahesh and will be based in Bermuda, pending approval by the Bermuda Immigration Authority. Nicole’s promotion follows her role as Senior Vice President of North America Supply Chain where she led a team responsible for a continuous journey of transformation within capabilities, planning, data and more. Within her scope was management of production and manufacturing teams across the region including the world’s largest premium rum distillery where BACARDÍ rum is produced in Puerto Rico, the home of ANGEL’S ENVY Kentucky Straight Bourbon, and the bottling facility in Jacksonville, Florida. With this appointment she now oversees all supply chain teams across the portfolio of Bacardi brands and around the globe. Prior to Bacardi, Nicole served in senior leadership supply chain roles across consumer brands including Nike and L’Oreal. She has been recognized for contributions to her field and named as one of 100 most Influential Women in Supply Chain in 2020 by Global Women Supply Chain Leaders.

Guillermo Donayre succeeds Nicole as the new SeniorVice President of North AmericaSupply Chain,taking on responsibility for the region while also maintaining responsibility for the PATRÓN tequila and agave production in Mexico. With three decades of experience in end-to-end operations and across different markets in Latin America, Guillermo has held a wide range of leadership roles during his career to date, including integrated supply planning, logistics, manufacturing, agriculture, procurement, and engineering for the food and beverage industry. He joined Bacardi in 2023 in Mexico and will relocate to the regional office of North America in Coral Gables, Florida. Pamela Chanona, Vice President Market Supply Chain Europe adds Latin America and the Caribbean to her responsibilities.

"We’re proud to appoint exceptional talent from within our organization into these critical roles," says Mahesh Madhavan, Bacardi Limited Chief Executive Officer. “These leaders have consistently demonstrated deep expertise, a strong commitment to our values, and the ability to lead at scale. Their appointments reflect not only their individual accomplishments, but also our belief in growing leadership from within our own teams."

Dave’s appointment is immediate, subject to Bermuda Immigration Authority approval. The appointments of Nicole, Guillermo and Pamela are effective January 1, 2026.

About Bacardi Limited

Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 163 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917778482/en/

Contacts

Jessica Merz, VP Global Corporate Communications, jmerz@bacardi.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye